Disease state may contribute to alteration on drug pharmacokinetics.
e purpose of this study was to determine the eff
ect of non-insulin dependent
diabetes mellitus (NIDDM) on the pharmacokinetics of glipizide.
An open, single-dose, parallel design was applied to the study. Glipizide
tablet (5 mg) was administered to healthy and diabetic human volunteers aft
night fast. Blood samples were collected, centrifuged and the plasma assayed using a
sensitive and validated reverse phase high performance liquid chromatography (RP-
HPLC) method. Various pharmacokinetic parameters were computed from the data
values for healthy and diabetic volunteers was 1878?195
and 1723?138 ng.h/ml respectively; these values were not signifi
erent (p >
for healthy volunteers was 3.04?0.27 h while that for diabetic subjects
was 2.98?0.16 h. Clearance for healthy and diabetic volunteers was 0.59?0.06 and
0.64?0.05 ml/min/kg, respectively. All the foregoing and other pharmacokinetic
parameters assessed not signifi
erent when compared for healthy and
diabetic volunteers (p > 0.05).
Although glipizide showed slightly more rapid clearance from the
body of diabetic volunteers than from healthy volunteers, this diff
erence, like those for
other pharmacokinetic parameters, was not signifi
cant (p > 0.05).
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals